Gene therapy for rheumatoid arthritis. Theoretical considerations
Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit th...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| Aporte de: |
| id |
todo:paper_1170229X_v12_n1_p29_Chernajovsky |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_1170229X_v12_n1_p29_Chernajovsky2023-10-03T16:08:10Z Gene therapy for rheumatoid arthritis. Theoretical considerations Chernajovsky, Y. Annenkov, A. Herman, C. Triantaphyllopoulos, K. Gould, D. Dreja, H. Moyes, S.P. Croxford, J.L. Mageed, R.A. Podhajcer, O.L. Baker, D. antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit the production or action of these cytokines and other mediators, has been achieved in experimental animal models. This new method of delivery can produce therapeutic effects at lower concentrations and in a local environment, overcoming the adverse effects that often accompany protein therapy. However, several technological and biological restraints preclude the immediate adaptation of this method to human treatment. Based on the experimental evidence, possible target therapeutic genes, cell types and vector systems that could be used are discussed in this article. Fil:Podhajcer, O.L. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans |
| spellingShingle |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans Chernajovsky, Y. Annenkov, A. Herman, C. Triantaphyllopoulos, K. Gould, D. Dreja, H. Moyes, S.P. Croxford, J.L. Mageed, R.A. Podhajcer, O.L. Baker, D. Gene therapy for rheumatoid arthritis. Theoretical considerations |
| topic_facet |
antirheumatic agent antisense oligonucleotide cytokine cytokine receptor immunoglobulin enhancer binding protein immunoglobulin fragment interleukin 1 interleukin 1 receptor blocking agent interleukin 10 plasmid DNA transforming growth factor beta1 tumor necrosis factor alpha tumor necrosis factor alpha antibody virus vector cell type clinical trial complement system gene targeting gene therapy human major clinical study mediator meta analysis priority journal review rheumatoid arthritis Arthritis, Rheumatoid Gene Therapy Genetic Vectors Humans |
| description |
Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit the production or action of these cytokines and other mediators, has been achieved in experimental animal models. This new method of delivery can produce therapeutic effects at lower concentrations and in a local environment, overcoming the adverse effects that often accompany protein therapy. However, several technological and biological restraints preclude the immediate adaptation of this method to human treatment. Based on the experimental evidence, possible target therapeutic genes, cell types and vector systems that could be used are discussed in this article. |
| format |
JOUR |
| author |
Chernajovsky, Y. Annenkov, A. Herman, C. Triantaphyllopoulos, K. Gould, D. Dreja, H. Moyes, S.P. Croxford, J.L. Mageed, R.A. Podhajcer, O.L. Baker, D. |
| author_facet |
Chernajovsky, Y. Annenkov, A. Herman, C. Triantaphyllopoulos, K. Gould, D. Dreja, H. Moyes, S.P. Croxford, J.L. Mageed, R.A. Podhajcer, O.L. Baker, D. |
| author_sort |
Chernajovsky, Y. |
| title |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_short |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_full |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_fullStr |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_full_unstemmed |
Gene therapy for rheumatoid arthritis. Theoretical considerations |
| title_sort |
gene therapy for rheumatoid arthritis. theoretical considerations |
| url |
http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky |
| work_keys_str_mv |
AT chernajovskyy genetherapyforrheumatoidarthritistheoreticalconsiderations AT annenkova genetherapyforrheumatoidarthritistheoreticalconsiderations AT hermanc genetherapyforrheumatoidarthritistheoreticalconsiderations AT triantaphyllopoulosk genetherapyforrheumatoidarthritistheoreticalconsiderations AT gouldd genetherapyforrheumatoidarthritistheoreticalconsiderations AT drejah genetherapyforrheumatoidarthritistheoreticalconsiderations AT moyessp genetherapyforrheumatoidarthritistheoreticalconsiderations AT croxfordjl genetherapyforrheumatoidarthritistheoreticalconsiderations AT mageedra genetherapyforrheumatoidarthritistheoreticalconsiderations AT podhajcerol genetherapyforrheumatoidarthritistheoreticalconsiderations AT bakerd genetherapyforrheumatoidarthritistheoreticalconsiderations |
| _version_ |
1807317509972426752 |